JP2022551969A5 - - Google Patents
Info
- Publication number
- JP2022551969A5 JP2022551969A5 JP2022522657A JP2022522657A JP2022551969A5 JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5 JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- cdr2
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915123P | 2019-10-15 | 2019-10-15 | |
| US62/915,123 | 2019-10-15 | ||
| PCT/US2020/055497 WO2021076564A1 (en) | 2019-10-15 | 2020-10-14 | Proteins binding nkg2d, cd16 and flt3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551969A JP2022551969A (ja) | 2022-12-14 |
| JP2022551969A5 true JP2022551969A5 (enExample) | 2023-10-19 |
Family
ID=75538862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522657A Pending JP2022551969A (ja) | 2019-10-15 | 2020-10-14 | Ｎｋｇ２ｄ、ｃｄ１６およびｆｌｔ３に結合するタンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240117054A1 (enExample) |
| EP (1) | EP4045538A4 (enExample) |
| JP (1) | JP2022551969A (enExample) |
| KR (1) | KR20220083770A (enExample) |
| CN (1) | CN115298217A (enExample) |
| AR (1) | AR120223A1 (enExample) |
| AU (1) | AU2020368163A1 (enExample) |
| BR (1) | BR112022007128A2 (enExample) |
| CA (1) | CA3153858A1 (enExample) |
| CL (2) | CL2022000928A1 (enExample) |
| CO (1) | CO2022004757A2 (enExample) |
| IL (1) | IL292261A (enExample) |
| MX (1) | MX2022004430A (enExample) |
| PE (1) | PE20221316A1 (enExample) |
| TW (1) | TW202128759A (enExample) |
| WO (1) | WO2021076564A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| JP2024537779A (ja) * | 2021-09-29 | 2024-10-16 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｂａｆｆ－ｒに結合するタンパク質 |
| US20230203202A1 (en) * | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| BR112020001972A2 (pt) * | 2017-07-31 | 2020-08-04 | Dragonfly Therapeutics, Inc. | proteínas de ligação a nkg2d, cd16 e flt3 |
| IL311488A (en) * | 2017-08-23 | 2024-05-01 | Dragonfly Therapeutics Inc | Proteins that bind D2NKG, 16CD, and tumor-associated antigen |
| MX2020002880A (es) * | 2017-09-14 | 2020-10-01 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). |
| MX2020008333A (es) * | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) * | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091976A1 (ru) * | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS |
-
2020
- 2020-10-14 BR BR112022007128A patent/BR112022007128A2/pt unknown
- 2020-10-14 US US17/769,160 patent/US20240117054A1/en active Pending
- 2020-10-14 AR ARP200102840A patent/AR120223A1/es unknown
- 2020-10-14 CN CN202080072319.9A patent/CN115298217A/zh active Pending
- 2020-10-14 AU AU2020368163A patent/AU2020368163A1/en active Pending
- 2020-10-14 MX MX2022004430A patent/MX2022004430A/es unknown
- 2020-10-14 PE PE2022000621A patent/PE20221316A1/es unknown
- 2020-10-14 TW TW109135528A patent/TW202128759A/zh unknown
- 2020-10-14 CA CA3153858A patent/CA3153858A1/en active Pending
- 2020-10-14 KR KR1020227016160A patent/KR20220083770A/ko active Pending
- 2020-10-14 EP EP20876627.9A patent/EP4045538A4/en active Pending
- 2020-10-14 WO PCT/US2020/055497 patent/WO2021076564A1/en not_active Ceased
- 2020-10-14 JP JP2022522657A patent/JP2022551969A/ja active Pending
-
2022
- 2022-04-12 CL CL2022000928A patent/CL2022000928A1/es unknown
- 2022-04-13 IL IL292261A patent/IL292261A/en unknown
- 2022-04-13 CO CONC2022/0004757A patent/CO2022004757A2/es unknown
-
2024
- 2024-12-17 CL CL2024003895A patent/CL2024003895A1/es unknown